UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 204

Sortiert nach

Quality of life in patients with psoriasis

Health and quality of life outcomes, 2006-06, Vol.4 (1), p.35-35, Article 35

2006

Link zum Volltext

Verfügbarkeit prüfen

Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family

Lung cancer (Amsterdam, Netherlands), 2024-05, Vol.191, p.107543-107543, Article 107543

2024

Link zum Volltext

Verfügbarkeit prüfen

A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma

European journal of cancer (1990), 2016-07, Vol.61, p.102-110

2016

Link zum Volltext

Verfügbarkeit prüfen

54: How reliable is the chest X-ray to diagnose lung cancer in symptomatic patients? An audit of a single South London NHS Trust

Lung cancer (Amsterdam, Netherlands), 2017, Vol.103, p.S25-S25

2017

Link zum Volltext

Verfügbarkeit prüfen

The Predictive Value of the G8 Questionnaire in Older Patients with Lung Cancer or Mesothelioma before Systemic Treatment

Clinical oncology (Royal College of Radiologists (Great Britain)), 2023-02, Vol.35 (2), p.e163-e172

2023

Link zum Volltext

Verfügbarkeit prüfen

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer

European journal of cancer (1990), 2016-05, Vol.59, p.65-78

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I dose escalation of pembrolizumab given concurrently with palliative thoracic radiotherapy (RT) for NSCLC

Annals of oncology, 2018-10, Vol.29, p.viii530-viii530

2018

Link zum Volltext

Verfügbarkeit prüfen

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

Lung cancer (Amsterdam, Netherlands), 2014-08, Vol.85 (2), p.141-146

2014

Link zum Volltext

Verfügbarkeit prüfen

167: A phase I/II trial of combination nab-paclitaxel and nintedanib or nab-paclitaxel and placebo in relapsed NSCLC adenocarcinoma (N3)

Lung cancer (Amsterdam, Netherlands), 2017, Vol.103, p.S77-S78

2017

Link zum Volltext

Verfügbarkeit prüfen

33: Adequacy of image-guided rebiopsies for molecular retesting in advanced NSCLC: a single centre experience

Lung cancer (Amsterdam, Netherlands), 2017, Vol.103, p.S15-S16

2017

Link zum Volltext

Verfügbarkeit prüfen

163 A randomised study comparing the effectiveness of acupuncture (A) or morphine (M) versus the combination (AM) for the relief of dyspnoea in patients with advanced non small cell lung cancer and mesothelioma

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S59-S59

2016

Link zum Volltext

Verfügbarkeit prüfen

A randomised assessment of the use of a quality of life questionnaire with or without intervention in patients attending a thoracic cancer clinic

European journal of cancer care, 2017-07, Vol.26 (4), p.e12402-n/a

2017

Link zum Volltext

Verfügbarkeit prüfen

47 Completion of the clinical audit cycle for delivery of molecular testing service for patients with non-small-cell lung cancer referred to the Royal Marsden

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S17-S17

2016

Link zum Volltext

Verfügbarkeit prüfen

72 The Royal Marsden NHS Foundation Trust experience of maintenance pemetrexed following first-line cisplatin/pemetrexed in advanced non-squamous lung cancer

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S26-S26

2016

Link zum Volltext

Verfügbarkeit prüfen

339 Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit (DDU) of the Royal Marsden Hospital (RMH)

European journal of cancer (1990), 2015-09, Vol.51, p.S67-S67

2015

Link zum Volltext

Verfügbarkeit prüfen

38 Patterns of relapse and detection method in patients with resected non-small cell lung cancer (NSCLC) – a single institution experience

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S15-S15

2014

Link zum Volltext

Verfügbarkeit prüfen

3 EGFR mutant circulating tumour DNA detection in advanced lung adenocarcinoma: optimising the application of a ctDNA diagnostic to real world clinical practice

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S2-S2

2016

Link zum Volltext

Verfügbarkeit prüfen

69: Outcomes with nintedanib and docetaxel in patients with relapsed NSCLC adenocarcinoma treated within the UK Nintedanib Individual Patient Supply programme

Lung cancer (Amsterdam, Netherlands), 2017, Vol.103, p.S32-S33

2017

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Medication Adherence and Associated Health Care Costs in an Older Population With Overactive Bladder Syndrome: A Longitudinal Cohort Study

The Journal of urology, 2006-03, Vol.175 (3), p.1067-1072

2006

Link zum Volltext

Verfügbarkeit prüfen

33 Outcomes of patients undergoing adjuvant platinum–vinorelbine chemotherapy for resected non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S12-S12

2013

Link zum Volltext

Verfügbarkeit prüfen

2207P Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom

Annals of oncology, 2023-10, Vol.34, p.S1140-S1140

2023

Link zum Volltext

Verfügbarkeit prüfen

1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond

Annals of oncology, 2020-09, Vol.31, p.S805-S805

2020

Link zum Volltext

Verfügbarkeit prüfen

1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience

Annals of oncology, 2020-09, Vol.31, p.S1020-S1021

2020

Link zum Volltext

Verfügbarkeit prüfen

EP08.02-124 Lorlatinib Treatment Related Adverse Events: Single Centre Real-World Experience in ALK and ROS1-driven NSCLC

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S461-S462

2022

Link zum Volltext

Verfügbarkeit prüfen

MA12.09 Frequency and Detectability of Uncommon EGFR Mutations in NSCLC

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S88-S89

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 204

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(176)
Mit Volltextzugriff
(183)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Humans
(43)
Life Sciences & Biomedicine
(41)
Physical Sciences
(26)
Female
(19)
Male
(18)
Technology
(16)
Aged
(14)
Hematology, Oncology And Palliative Medicine
(14)
Oncology
(14)
Physics
(14)
Adult
(13)
Middle Aged
(12)
Animals
(11)
Biological And Medical Sciences
(11)
Physics, Applied
(11)
Pulmonary/respiratory
(11)
Engineering
(10)
Lamps
(9)
Plasmas
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Lung Cancer
(22)
Value In Health
(14)
Journal Of Thoracic Oncology
(13)
Journal Of Applied Physics
(12)
Annals Of Oncology
(11)
Applied Physics Letters
(6)
Plos One
(4)
The Journal Of Dermatological Treatment
(4)
Biofouling
(3)
Cancer Cell
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Quality of life in patients with psoriasis

Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family

A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma

54: How reliable is the chest X-ray to diagnose lung cancer in symptomatic patients? An audit of a single South London NHS Trust

The Predictive Value of the G8 Questionnaire in Older Patients with Lung Cancer or Mesothelioma before Systemic Treatment

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer

Phase I dose escalation of pembrolizumab given concurrently with palliative thoracic radiotherapy (RT) for NSCLC

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

167: A phase I/II trial of combination nab-paclitaxel and nintedanib or nab-paclitaxel and placebo in relapsed NSCLC adenocarcinoma (N3)

33: Adequacy of image-guided rebiopsies for molecular retesting in advanced NSCLC: a single centre experience

163 A randomised study comparing the effectiveness of acupuncture (A) or morphine (M) versus the combination (AM) for the relief of dyspnoea in patients with advanced non small cell lung cancer and mesothelioma

A randomised assessment of the use of a quality of life questionnaire with or without intervention in patients attending a thoracic cancer clinic

47 Completion of the clinical audit cycle for delivery of molecular testing service for patients with non-small-cell lung cancer referred to the Royal Marsden

72 The Royal Marsden NHS Foundation Trust experience of maintenance pemetrexed following first-line cisplatin/pemetrexed in advanced non-squamous lung cancer

339 Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit (DDU) of the Royal Marsden Hospital (RMH)

38 Patterns of relapse and detection method in patients with resected non-small cell lung cancer (NSCLC) – a single institution experience

3 EGFR mutant circulating tumour DNA detection in advanced lung adenocarcinoma: optimising the application of a ctDNA diagnostic to real world clinical practice

69: Outcomes with nintedanib and docetaxel in patients with relapsed NSCLC adenocarcinoma treated within the UK Nintedanib Individual Patient Supply programme

Predictors of Medication Adherence and Associated Health Care Costs in an Older Population With Overactive Bladder Syndrome: A Longitudinal Cohort Study

33 Outcomes of patients undergoing adjuvant platinum–vinorelbine chemotherapy for resected non-small cell lung cancer (NSCLC)

2207P Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom

1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond

1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience

EP08.02-124 Lorlatinib Treatment Related Adverse Events: Single Centre Real-World Experience in ALK and ROS1-driven NSCLC

MA12.09 Frequency and Detectability of Uncommon EGFR Mutations in NSCLC

Suchergebnisse filtern